DaVita Q3 cash flow ops down 26% as growth stalls

• DaVita (NYSE:DVA) Q3 results:
• Revenues: $2,924.1M (+0.7%); Dialysis services: $2,781.7M (+0.2%).
• Net income: $158.7M (+10.7%); non-GAAP net income: $223.3M (-3.7%); EPS: $1.28 (+34.7%); non-GAAP EPS: $1.80 (+17.6%).
• Cash flow ops: $482.7M (-25.9%).
• Free cash flow from continuing ops: $286.8M (-43.4%).
• Dialysis treatments: 7,656,173 (+1.1%).
• Revenue negatively impacted by a decrease in commercial revenue per treatment, unfavorable changes in government payor mix and a decline in calcimimetics revenue per treatment, partially offset by increases in inpatient dialysis service revenue and Medicare rates due to the temporary suspension of Medicare sequestration.
• 2020 guidance: Revenue: $11,500M - 11,600M from $11,500M - 11,700M; non-GAAP EPS: $7.35 - 7.60 from $6.25 - 6.75; free cash flow: $1,100M - 1,250M from $800M - 1,000M.
• https://seekingalpha.com/news/3628730-davita-q3-cash-flow-ops-down-26-growth-stalls